Natrecor (nesiritide) has been linked to a significantly higher risk of worsened kidney function in heart failure patients treated with the drug. A team composed of researchers from the North Shore University Hospital in New York and the University of Michigan analyzed data from controlled trials of the drug conducted by the manufacturer, Scios, Inc., a unit of Johnson & Johnson. The researchers analyzed medical records of 1200 patients and found a 40-50% higher risk of kidney dysfunction when used for the treatment of decompensated heart failure.

Decompensated heart failure is the most common reason for hospitalization among people over the age of 65 in the U.S. A chronic condition, heart failure occurs when the heart loses its ability to pump blood effectively. The heart often enlarges, causing build up of fluid. Symptoms include breathlessness, chest pain and a loss of energy. Diuretics are the main treatment for this condition, known to affect over 5 million Americans.

Natrecor (nesiritide) is given in approximately 10% of heart failure-related hospitalizations. It is thought to improve symptoms by stimulating the heart to pump blood more forcefully. Original clinical studies showed that Natrecor (nesiritide) could be associated with azotemia, an accumulation of urea in the blood that is usually excreted in urine. Natrecor (nesiritide) was considered an important reason for Johnson & Johnson’s acquisition of Scios in 2003.

Source: “Johnson’s Natrecor worsens kidney risk-study,” Reuters.com, March 21, 2005.